Transmisiones mundiales acerca de la esclerosis múltiple progresiva

Advances in treatment and research.

Global webcast on new treatments for progressive MS

Recent advances and promising researches

Du Pré Grants

MSIF Du Pré Grants enable multiple sclerosis researchers and clinicians to undertake short placements in established MS research centres and clinics

Transmisión mundial acerca de la desafíos cognitivos para personas con esclerosis múltiple progresiva

Catch up on advances in treatment and research.

Adaptive clinical trial in Australia offers new hope for progressive MS

The first adaptive clinical trial for Australians living with MS

Join us for the webcast on cognitive challenges in progressive MS

Advances in treatment and research.

Transmisión por Internet mundial sobre el fin de la progresión de la esclerosis múltiple

Research advances that could lead to breakthrough treatments in progressive MS

‎3 millones de euros para avanzar en la investigación con miras a detener la progresión de la esclerosis múltiple

International Progressive MS Alliance invests €3 million in drug discovery project to develop therapies to stop MS progression.

Transmisión mundial sobre el dolor en la esclerosis múltiple progresiva

Answering questions and exploring advances in research

Progressive MS research

The International Progressive MS Alliance works to speed up the development of treatment for progressive MS

Cómo resolver el misterio de la progresión: la clave de los nuevos tratamientos para la esclerosis múltiple progresiva

Catch up with the latest webcast on unraveling the mystery of progression and identifying new targets for treatments

Transmisión global sobre el final de la esclerosis múltiple progresiva

Learn about important, new research initiatives that will fuel the development of breakthrough treatments for progressive MS.  

Desafíos a los que se enfrentan las investigaciones en EM

Thousands of scientists are undertaking research into all aspects of MS, furthering our understanding of the disease and how to prevent, treat and manage it.

Mapeo de la agenda de investigación mundial para eliminar la esclerosis múltiple progresiva

Leaders of the International Progressive MS Alliance have published a paper proposing a global research strategy to prioritise and coordinate the efforts needed to find more and better treatments, and improve quality of life of people living with progressive MS.

2021 McDonald Fellowships and Du Pré Grant recipients announced

MSIF is proud to announce the recipients of the 2021 McDonald Fellowships and Du Pré Grants, from Argentina, Brazil, Egypt, Iran, and Tunisia

Progressive MS Alliance – MS stories from across the world

Find out about the lives of seven people affected by progressive MS.

El profesor Alan Thompson gana el prestigioso premio Charcot de EM

Professor Thompson wins the 2021 lifetime achievement award for outstanding research into the understanding and treatment of MS

La Alianza financia 19 becas al desafío de la investigación en la búsqueda de respuestas para la progresión

In time for World MS Day, €1,425,000 has been awarded to help identify new therapeutic targets in progressive MS

Respuesta a las preguntas sobre el tratamiento y la investigación de la EM progresiva: ¡Ver en español!

Watch the International Progressive MS Alliance webcast

Clinical research and trials

Research and clinical trials are taking place around the world, trying to find and improve treatments for MS

Recibe información sobre los últimos avances en los tratamientos para EM progresiva

A first-of-its-kind global research network funded by the International Progressive MS Alliance aims to develop new, effective treatments for progressive MS.

EM progresiva y novedosos tratamientos en rápido desarrollo

Global webcast on 4 March

Investigación sobre cómo combatir la inflamación del cerebro en la esclerosis múltiple gracias a la información del intestino

This paper was first published in Nature January 2021

Anunciamos a los beneficiarios de las becas McDonald y las subvenciones Du Pré de 2020

MSIF is proud to announce the recipients of the 2020 McDonald Fellowships and Du Pré Grants, from Iran, Zambia, Brazil, Turkey, and Argentina

Join the discussion on symptom management & well-being in progressive MS

Register for the Progressive MS Alliance's Facebook Live event

El riesgo de la EM primaria progresiva puede estar relacionado con genes que causan otras enfermedades cerebrales 

Genetic screening of people with primary progressive MS has shown that four rare genetic changes, which are known to cause other neurological diseases, may play a role in primary progressive MS.

Un biomarcador potencial para la EM progresiva

The use of neurofilament light chain (NfL) as a biomarker could revolutionise clinical trials in progressive MS.

‎¿Cómo agilizamos la aplicación de tratamientos decisivos para la vida de personas con EM progresiva?

Join the discussion about research breakthroughs that could accelerate new treatments for people with progressive MS

Mitocondrias con gran energía: una posible vía para tratar la EM progresiva

New research funded by the International Progressive MS Alliance looks at ways that nerve fibres protect themselves from damage.

Answering today’s big questions in progressive MS

Watch the International Progressive MS Alliance webcast here

Discovering life-changing treatments for progressive MS

An International Progressive MS Alliance global webcast

Los daños en la médula cervical y la discapacidad en la EM

Cord lesion load and spinal cord atrophy may contribute to disability in people with progressive MS

First treatment for people with secondary progressive MS in Europe is approved

An important milestone for people with secondary progressive MS in Europe

Let’s talk about symptoms and well-being in progressive MS

Register for the Progressive MS Alliance's Facebook Live event on symptom management and well-being in progressive MS

Challenges in Progressive MS Awards: taking risks to reap rewards

Progressive MS Awards

La primera organización de EM en América Latina se une a la Alianza Internacional de la EM Progresiva

The International Progressive MS Alliance is growing!

Global webcast on solving progressive MS: progress achieved and hope for the future

Results released from first multi-drug clinical trial in MS

The results of the MS-SMART trial, an innovative trial testing multiple drugs at the same time, have ruled out three repurposed drugs for the treatment of progressive MS.

Una medicación para el asma podría retrasar la atrofia cerebral en la EM progresiva

A phase II clinical trial has shown ibudilast, a repurposed asthma medication, can slow down the rate of brain tissue loss in progressive MS by almost half compared to a placebo treatment.

Conferencia de la Alianza de la EM Progresiva: rehabilitación y control de los síntomas 

Researchers, clinicians and people living with MS, from around the world converged on the city of Toronto in Canada for the 3rd Congress of the International Progressive MS Alliance.

El sinuoso camino del avance de la EM

How the biological processes cause progression in different types of MS.

El siponimod es una gran esperanza para las personas con EM secundaria progresiva

A new, international clinical trial has shown that siponimod can slow progression in people with secondary progressive MS.

Un medicamento antidepresivo podría servir para tratar la EM progresiva

Screening of almost 250 medications has identified clomipramine as a possible treatment for progressive MS.

Aprobado en Europa el primer tratamiento para la EM primaria progresiva

The European Commission has approved the first disease-modifying therapy, ocrelizumab, for early primary progressive MS (PPMS).

European Medicines Agency recommends market authorisation for ocrelizumab (Ocrevus) in EU

The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS

Primer tratamiento autorizado para la EM progresiva primaria en los EE. UU.

Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US

Neurobiología e inmunología

Neurobiology and immunology are key areas of MS research

¿Qué ocurrió en el congreso del ECTRIMS 2016?

Researchers and health professionals gather for the latest updates and research findings on treatment, care and management of MS

Personas con EM ayudan a dirigir la investigación sobre EM progresiva

Video from Caroline Sincock who recently joined the International Progressive MS Alliance

¿Qué ha pasado en ECTRIMS?

Our highlights from the world’s largest scientific conference on multiple sclerosis

Segundo Congreso Científico de la Alianza internacional de EM Progresiva

Challenges and next steps considered

Progressive MS webinar transcript

Full text of our 2014 webinar with experts on progressive MS

Rituximab intratecal no es eficaz en el tratamiento de la esclerosis múltiple progresiva

A recent study has failed to show any benefit for Rituximab in people with secondary progressive MS

Fingolimod no es eficaz en el tratamiento de la esclerosis múltiple primaria progresiva

A new trial has failed to show Fingolimod has any effect of in primary-progressive MS

Resultados de un estudio observacional a largo plazo sobre la EM

Long-term follow-up studies could help determine predictive factors for long-term clinical outcomes

Nuevo objetivo para entender la progresión secundaria de la EM

Chemical in the brain involved in signaling may play a role in progressive MS

El Profesor Giancarlo Comi gana el Premio Charcot

The Charcot Award recognises a lifetime of achievement in MS research

La Alianza internacional de EM progresiva financia la colaboración de investigación global

Collaborative Network Planning Awards Granted as part of €22 million global effort to End Progressive MS

¿Qué pasó en la Jornada ‘Living with MS day’?

On 6 October, 650 people affected by MS gathered in Barcelona for the ‘Living with MS Day’ event

Ampliación de la información sobre los efectos positivos del Ocrelizumab en EM primaria progresiva

The results from a phase III clinical trial of Ocrelizumab in primary progressive MS are announced at ECTRIMS

Retraso del desarrollo de la esclerosis múltiple progresiva secundaria

Recovery from early relapses can potentially delay or prevent onset of progressive MS

Características de la esclerosis múltiple primaria progresiva

Researchers in Canada have investigated the natural history of 500 people with primary progressive MS

Biomarcadores de la inflamación en la EM progresiva

There is a need to identify direct biomarkers of inflammation within the central nervous system

Un método no invasivo para identificar la progresión de la EM

Researchers are looking for new biomarkers of disease, which could also recognise progression of MS in a reasonable time

La médula espinal se ve afectada en la fase temprana de la EM primaria progresiva

Study suggests that early spinal neurodegeneration may underlie clinical impairment

La Alianza de EM Progresiva busca miembros no profesionales para su Comité Científico Directivo

Three people needed to help shape the work of the Alliance

Los cambios en el tálamo como medida de la progresión de la EM

Study supports a link between the development of grey matter disease and a progressive MS phenotype

Nuevos marcadores para predecir la progresión de la EM

Neurofilaments are a good way to monitor nerve damage and treatments in progressive MS

Los fármacos modificadores de la enfermedad podrían reducir el avance de la discapacidad en la EM recurrente-remitente

Researchers found a lower risk of disability progression at the 10-year follow-up in the RRMS group compared with historical cohorts

La Alianza para la EM Progresiva crece

The Alliance has been joined by four MS International Federation member organisations

La EM progresiva y los medicamentos modificadores de la enfermedad

Patients with secondary progressive MS who have ongoing relapses may benefit from continuing immunomodulatory therapies after onset of progressive MS

Decepcionantes resultados del ensayo con fingolimod en la EM primaria progresiva

The results suggest that primary progressive and relapsing forms of MS have different underlying mechanisms

Alliance anuncia becas de investigación para la EM progresiva

The Progressive MS Alliance has awarded its first round of 22 research grants to investigators in nine countries

Tipos de EM

MS comes in several forms, including clinically isolated syndrome, relapsing-remitting MS, secondary progressive MS and primary progressive MS.